Indication
Extraskeletal Myxoid Chondrosarcoma
4 clinical trials
6 products
Product
SeclidemstatClinical trial
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select SarcomasStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Product
TopotecanClinical trial
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)Status: , Estimated PCD: 2025-12-01
Product
CyclophosphamideClinical trial
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)Status: Active (not recruiting), Estimated PCD: 2019-06-30
Product
DoxorubicinProduct
IfosfamideProduct
PazopanibClinical trial
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)Status: Completed, Estimated PCD: 2019-12-01